ArticleDiscover oncology2025
Expressions, immune associations, and prognostic values of mitochondrial ribosomal protein MRPL3 in the pan cancer landscape.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMRPL3, a member of the mitochondrial ribosomal family, is involved in the translation of mitochondria-related proteins. However, its role in tumors remains unclear.
objectiveTo elucidate the oncogenic role and prognostic significance of MRPL3 in cancer.
methodsWe conducted a pan-cancer analysis of MRPL3 using various databases, bioinformatics and statistical tools, as well as tissue microarray analysis.
resultsMRPL3 was generally upregulated in tumors compared to normal tissues. Its expression showed a negative correlation with immunogenic markers, immune cell infiltration, and immune checkpoint genes (ICGs) in most cancers, suggesting an immunosuppressive role in the tumor microenvironment (TME). Genes interacting with and similar to MRPL3 were involved in key signaling pathways across cancers. MRPL3 overexpression was frequently associated with poor prognosis and identified as an independent prognostic risk factor in KIRC, LUSC, LIHC, MESO, UCEC, and PAAD.
conclusionMRPL3 is overexpressed in multiple cancers and plays an immunosuppressive role, significantly correlating with poor prognosis, indicating its potential as a therapeutic target in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.